Oral JAK inhibitor or biologic: 88.9% of US dermatologists start a pill-seeking eczema patient on the JAK, and only a $150 a month gap tips most to the biologic
88.9% of US dermatologists on the Brox panel would start a healthy 35-year-old with moderate-to-severe eczema who asks for a pill on an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month, falling to 81.7% at a $30 monthly gap, 69.0% at $75 and 46.8% at $150 (n=126, November 2026).
- Who was asked
- US dermatologists, 126 clones, US
- When
- November 2026 (fielded 2 November 2026)
- How
- Predicted responses from Brox clones, each built from a long-form interview with a real person.
- What changed from the obvious question
- The obvious question lists the reasons dermatologists prefer or avoid JAK inhibitors, which clinical reviews and the boxed warning literature already cover. This study priced the decision instead: one pill-seeking patient who suits an oral JAK, then three fully written out-of-pocket gaps against a $0 biologic, so the page can say how much a pill preference is worth before dermatologists move to the biologic, and then which single brake they name.
Section 01: What the panel said
- #
88.9%
For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more.
base 126
- #
65.1%
65.1% name the boxed safety warning as the main thing that would make them hold back from an oral JAK inhibitor for a patient who asks for a pill, against 12.7% for insurance and prior authorization hurdles, 7.1% for less long-term experience and 6.3% for routine blood test monitoring; 8.7% say nothing would hold them back.
base 126 · contrast
- #
86.6%
Of the 82 dermatologists who name the boxed warning as their main brake, 86.6% (71 of 82) would still start this low-risk patient on the oral JAK inhibitor when both options cost $0.
base 82 · Dermatologists naming the boxed safety warning as the main brake · contrast
- #
39
39 of the 59 dermatologists who would still start the oral JAK inhibitor at $150 a month more say in their answer that copay cards or manufacturer assistance would bring that cost down, so the top rung measures belief in assistance as much as tolerance of the price.
base 59 · Dermatologists still choosing the oral JAK at a $150 monthly gap · caveat
For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more.
02Where does the pill preference give way to cost?
Between $75 and $150 a month. Of the 126 dermatologists, 112 start the pill-seeking patient on the oral JAK inhibitor when both options cost $0. 9 move to the biologic when the JAK costs $30 a month more, 16 more at $75 and 28 more at $150, so the steps grow as the gap does and the largest one is the last. Nobody moves back: every dermatologist who chooses the biologic at a smaller gap also chooses it at a larger one.
The majority holds until the top rung. At a $75 monthly gap, 69.0% (n=126) still choose the oral JAK; at $150, 46.8% do and 53.2% choose the biologic. 14 of 126 choose the biologic at every price, including when both are free to the patient.
03Why does the boxed warning not stop them for this patient?
Because dermatologists apply the warning to patients with risk factors, and this patient has none. The boxed safety warning is the main brake for 65.1% (n=126), far ahead of insurance and prior authorization hurdles at 12.7% and routine blood test monitoring at 6.3%. Yet 71 of the 82 who name it would still start this 35-year-old with no cardiovascular, clot or cancer risk factors on the oral JAK when cost is equal.
Their answers describe the warning as a screen rather than a veto: they check cardiovascular, clotting and cancer history first, and once the patient clears it, the patient's wish for a pill decides.
04How real is a $150 monthly gap to a prescriber?
Less real than it looks. Of the 59 dermatologists who would still start the oral JAK at $150 a month more, 39 say in their answer that copay cards, manufacturer assistance or bridge programs would bring that cost down. The scenario did not mention any assistance; they brought it in themselves.
So the top rung measures two things at once: how much a pill preference is worth, and how much prescribers expect a copay card to absorb. That fits what other Brox pages found when cost decides between two similar biologics with no patient preference in play: there the plan's choice wins (read that page), and coverage is what holds back the step from topicals to a systemic (read that page).
05What would a brand or market access team do with this?
- Our reading, not the panel's answer: for an oral therapy, the patient asking for a pill is the strongest lever, carrying 69.0% (n=126) of dermatologists through a $75 monthly gap.
- Our reading: copay support sits inside the prescribing decision. 39 of the 59 who hold at $150 count on it, so a program that is hard to use or capped is likely to show up as lost starts at the top of the ladder.
- Our reading: safety messaging works as a screen. 65.1% (n=126) name the boxed warning first, and the clear route through it is a defined low-risk patient profile rather than a general reassurance.
06What do people also ask?
- What share of dermatologists would prescribe an oral JAK inhibitor to an eczema patient who asks for a pill? 88.9% (n=126) would start a healthy 35-year-old on it rather than a biologic when both cost the patient $0 a month.
- At what out-of-pocket gap do most dermatologists switch from an oral JAK inhibitor to a biologic? Between $75 and $150 a month: 69.0% still choose the JAK at $75 more and 46.8% at $150 more (n=126).
- How many dermatologists say the boxed warning holds them back from JAK inhibitors? 65.1% (n=126) name the boxed safety warning as the main thing, against 12.7% for insurance and prior authorization hurdles.
Section 07: What they said, and the interview line it rests on
“An oral JAK inhibitor, hands down. That's an easy call for me. In my practice, I don't have that reflex where a biologic has to be tried first and a JAK is only something you escalate to later. I treat oral JAKs and biologics as genuinely co-equal first-line systemic options for moderate-to-severe AD. When I'm sitting across from a patient, I run through my mental filters fast: first is contraindications, and here you've got a healthy thirty-five-year-old with no cardiovascular risk, no blood clot history, and no malignancy concerns. The safety profile lines up cleanly. The second filter is patient preference and fit. If a patient is sitting there telling me they dislike needles, don't want injections, and are actively asking for a pill—and insurance is covering both at zero dollars out of pocket—there is zero clinical reason to force an injectable on them. An oral JAK gives them the once-daily pill they want, plus that rapid speed of onset where the itch starts backing down in days. So I would start this patient on an oral JAK inhibitor without hesitation.”
Predicted from this line in the interview
“absent a contraindication, I genuinely let the patient and the disease specifics drive it, and the patient choosing the oral pill is a totally legitimate, well-supported choice, not a second-tier one.”
“I would start this patient on an injectable biologic. Even though the patient dislikes injections and asks for a pill—which is something we hear quite often—there are several key factors here. First, my go-to first-line systemic therapy for moderate-to-severe atopic dermatitis is an injectable biologic, keeping JAK inhibitors as more of a second-line option. Second, from a safety standpoint, biologics have a cleaner long-term profile without the black box warnings that JAKs carry. Most importantly, the financial reality here is decisive. Paying $150 a month out of pocket for an oral medication is $1,800 a year, whereas the injectable biologic is completely covered at $0 a month. That kind of recurring out-of-pocket expense directly affects compliance and long-term adherence. I'd explain this difference to the patient, reassure them about modern autoinjectors—which are usually much easier and less painful than people expect—and offer to have our staff walk them through the first injection in the clinic. If they genuinely cannot tolerate the injections or fail therapy down the line, the oral JAK inhibitor remains a great second-line backup.”
Predicted from this line in the interview
“my go-to is probably the injectable biologics, and then JAK inhibitors would be probably more of a second-line treatment for systemic therapy.”
“If an adult patient specifically asks for a pill, the main thing that would make me pause or hold back is their cardiovascular and safety risk profile—specifically the boxed safety warning covering MACE and VTE risks. If they are young, otherwise healthy, and have clean labs, I'm comfortable prescribing a JAK inhibitor. But if they're older, have significant comorbidities, or have a personal history of MIs, strokes, or blood clots, that's where I hesitate and actively steer them toward safer systemic options like biologics instead.”
Predicted from this line in the interview
“I definitely do look at risk factors, especially the MACE risk, um, before I would ever start a JAK inhibitor. So if somebody already has had MIs or, um, strokes, that it's a very heavy discussion, and there have been times where I've steered patients away from JAK inhibitors.”
Section 08: How much should you trust this?
What we would defend
- The ladder: the share starting the oral JAK falls from 88.9% to 81.7% to 69.0% to 46.8% (n=126) as its monthly cost to the patient rises from $0 to $30, $75 and $150 against a $0 biologic; every clone moves in one direction only and each rung's reasoning cites its own price.
- The boxed safety warning as the main named brake on the oral JAK, 65.1% (n=126), well ahead of insurance and prior authorization hurdles at 12.7%.
- That naming the warning does not stop most dermatologists prescribing to a low-risk patient who asks for a pill: 71 of the 82 who name it would still start the JAK at equal cost.
What we would not
- The $150 rung as pure price tolerance: 39 of the 59 who still choose the JAK at $150 say copay cards or manufacturer assistance would bring the cost down, so the 46.8% (n=126) partly measures belief in assistance.
- The 88.9% as a general rate of JAK use: the patient was written as the ideal oral candidate (35, no cardiovascular, clot or cancer risk factors, asking for a pill), and a patient with risk factors was not tested.
- A precise tipping point: only $30, $75 and $150 were tested, so the majority flips somewhere between $75 and $150 a month.
- Any split by age, gender or region: gender is missing for 54 of 126 clones and age for 64, and every recorded segment is small.
The main limitation
These are 126 clones of US dermatologists stating what they would do for one written patient, with the biologic held at $0 and no copay assistance mentioned in the scenario; stated choice for an ideal candidate is not prescribing behavior.
Section 09: How was this run?
| Segment | Clones |
|---|---|
| Women | 37 |
| Men | 35 |
| Gender not recorded | 54 |
Question wording as fielded
- Do you currently prescribe systemic treatment (biologics or oral JAK inhibitors) for adults with moderate-to-severe atopic dermatitis?
- An adult patient aged 35 with moderate-to-severe atopic dermatitis and no cardiovascular, blood clot or cancer risk factors has not responded to topical treatment, dislikes injections and asks for a pill. Their insurance covers both an oral JAK inhibitor and an injectable biologic, and both cost the patient $0 a month. Which would you start this patient on?
- An adult patient aged 35 with moderate-to-severe atopic dermatitis and no cardiovascular, blood clot or cancer risk factors has not responded to topical treatment, dislikes injections and asks for a pill. Their insurance covers both an oral JAK inhibitor and an injectable biologic. The injectable biologic costs the patient $0 a month and the oral JAK inhibitor costs the patient $30 a month. Which would you start this patient on?
- An adult patient aged 35 with moderate-to-severe atopic dermatitis and no cardiovascular, blood clot or cancer risk factors has not responded to topical treatment, dislikes injections and asks for a pill. Their insurance covers both an oral JAK inhibitor and an injectable biologic. The injectable biologic costs the patient $0 a month and the oral JAK inhibitor costs the patient $75 a month. Which would you start this patient on?
- An adult patient aged 35 with moderate-to-severe atopic dermatitis and no cardiovascular, blood clot or cancer risk factors has not responded to topical treatment, dislikes injections and asks for a pill. Their insurance covers both an oral JAK inhibitor and an injectable biologic. The injectable biologic costs the patient $0 a month and the oral JAK inhibitor costs the patient $150 a month. Which would you start this patient on?
- For an adult with moderate-to-severe atopic dermatitis who asks for a pill, what is the main thing that would make you hold back from prescribing an oral JAK inhibitor?
What was not asked, and why
No medicine, brand or manufacturer was named. The patient was always the same low-risk 35-year-old who asks for a pill; a patient with cardiovascular, clot or cancer risk factors, a biologic with a cost to the patient, and a scenario with or without a copay card were not tested. Ask Brox fielded the six questions as written and added none of its own.
What changed from the obvious question
The obvious question lists the reasons dermatologists prefer or avoid JAK inhibitors, which clinical reviews and the boxed warning literature already cover. This study priced the decision instead: one pill-seeking patient who suits an oral JAK, then three fully written out-of-pocket gaps against a $0 biologic, so the page can say how much a pill preference is worth before dermatologists move to the biologic, and then which single brake they name.
Fielded through Ask Brox on 2 November 2026.
More on How doctors decide what to prescribe · Pricing and price sensitivity · Pharma & HCP · HCP Dermatologists (US) panel
Ask this of your own customers: humans@brox.ai
Related insights
All in this topic-
Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
65.2% 65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine (base 198)
Read -
Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150
37.1% 37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. (base 70)
Read -
New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month
22.9% 22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. (base 70)
Read -
Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
66.7% Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. (base 198)
Read